Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome?

Journal of the American Society of Nephrology

Volumn 18, Issue 9, 2007, Pages 2457-2460

  Desch, Karl ^a   Motto, David ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANTIBODY PRODUCTION; BINDING SITE; BLOOD CLOTTING DISORDER; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; ERYTHROCYTE; GENE EXPRESSION; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; LEUKOCYTE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SHIGELLA DYSENTERIAE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 34548510566     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2007010062     Document Type: Review

References (15)

1. Moake JL: Thrombotic microangiopathies. N Engl J Med 347: 589-600, 2002
2. Tsai HM: The molecular biology of thrombotic microangiopathy. Kidney Int 70: 16-23, 2006
3. Levy GG, Motto DG, Ginsburg D: ADAMTS13 turns 3. Blood 106: 11-17, 2005
4. Ruggenenti P, Noris M, Remuzzi G: Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 60: 831-846, 2001
5. Lopez JA, Dong JF: Cleavage of von Willebrand factor by ADAMTS-13 on endothelial cells. Semin Hematol 41: 15-23, 2004
6. Ray PE, Liu XH: Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol 16: 823-839, 2001
7. Tarr PI, Gordon CA, Chandler WL: Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365: 1073-1086, 2005
8. Noris M, Remuzzi G: Hemolytic uremic syndrome. J Am Soc Nephrol 16: 1035-1050, 2005
9. Karpman D, Papadopoulou D, Nilsson K, Sjogren AC, Mikaelsson C, Lethagen S: Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. Blood 97: 3100-3108, 2001
10. Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL, Igarashi T, Tarr PI: Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 346: 23-32, 2002
11. Kavanagh D, Goodship TH, Richards A: Atypical haemolytic uraemic syndrome. Br Med Bull 77-78: 5-22, 2006
12. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, Lopez-Trascasa M, Sanchez-Corral P, Morgan BP, Rodriguez de Cordoba S: Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 104: 240-245, 2007
13. Nolasco LH, Turner NA, Bernardo A, Tao Z, Geary TG, Dong JF, Moake JL: Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 106: 4199-4209, 2005
14. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D: Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 115: 2752-2761, 2005
15. Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G; International Registry of Recurrent and Familial HUS/TTP: Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 16: 1177-1183, 2005